Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2145859 | 0.74 | JAK3 (0.33) | ALDH1A1 | |
| SCHEMBL2145643 | 0.73 | JAK3 (0.35) | ALDH1A1DGAT1 | |
| SCHEMBL11173111 | 0.72 | ELANE (0.37) | ELANEKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL25371620 | 0.70 | MEN1 (0.33) | DGAT1 | |
| SCHEMBL13366320 | 0.69 | PIM1 (0.33) | — | |
| SCHEMBL9750631 | 0.69 | CYP1A2 (0.32) | — | |
| SCHEMBL25406087 | 0.69 | MEN1 (0.32) | — | |
| SCHEMBL9750601 | 0.67 | CCNE2 (0.32) | — | |
| SCHEMBL9750662 | 0.66 | KDM4E (0.40) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL2548958 | 0.66 | AGTR1 (0.45) | ALDH1A1HPGDSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716312-B2 | Inhibitors of diacylglycerol acyltransferase | MERCK SHARP & DOHME CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2367598-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110224137-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP. | 2011-09-15 | — | — | US | disclosed |
| US-20110224137-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP. | 2011-09-15 | — | — | US | disclosed |
| US-20110224137-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP. | 2011-09-15 | — | — | US | disclosed |
| US-20110224136-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP | 2011-09-15 | — | — | US | disclosed |
| US-20110224136-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP | 2011-09-15 | — | — | US | disclosed |
| US-20110224136-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP | 2011-09-15 | — | — | US | disclosed |
| EP-2346853-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010059602-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059602-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059606-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059606-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224136-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | ELANE 3564/4885KDM4E 1365/4885SLC16A3 1738/4885 |
| US-20110224137-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | ELANE 3549/4885KDM4E 1403/4885SLC16A3 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.